Fcpm Iii Services B.v is an investment fund managing more than $678 billion ran by V. Mulder. There are currently 6 companies in Mulder’s portfolio. The largest investments include Dyne Therapeutics and Newamsterdam Pharma Company, together worth $504 billion.
As of 1st August 2024, Fcpm Iii Services B.v’s top holding is 7,845,364 shares of Dyne Therapeutics currently worth over $277 billion and making up 40.8% of the portfolio value.
Relative to the number of outstanding shares of Dyne Therapeutics, Fcpm Iii Services B.v owns less than 0.2% of the company.
In addition, the fund holds 11,831,461 shares of Newamsterdam Pharma Company worth $227 billion.
The third-largest holding is Engene Holdings Inc worth $85.3 billion and the next is Replimune Inc worth $43.8 billion, with 4,866,449 shares owned.
Currently, Fcpm Iii Services B.v's portfolio is worth at least $678 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
The Fcpm Iii Services B.v office and employees reside in Naarden, Netherlands. According to the last 13-F report filed with the SEC, V. Mulder serves as the Directors at Fcpm Iii Services B.v.
In the most recent 13F filing, Fcpm Iii Services B.v revealed that it had opened a new position in Bicycle Therapeutics plc and bought 2,122,892 shares worth $43 billion.
The two most similar investment funds to Fcpm Iii Services B.v are Magnolia Group and Praesidium Investment Management. They manage $678 billion and $678 billion respectively.
Fcpm Iii Services B.v’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 53.6% of
the total portfolio value.
The fund focuses on investments in the United States as
33.3% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are large-cap stocks.
Stocks with a size of more than $10 billion in market cap make up
approximately 0.1% of the total holdings value.
On the other hand, small-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $929 million.
These positions were updated on August 8th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Dyne Therapeutics, Inc. |
No change
7,845,364
|
$276,862,896,000 | 40.83% |
| Newamsterdam Pharma Company |
No change
11,831,461
|
$227,282,366,000 | 33.52% |
| Engene Holdings Inc |
No change
11,556,099
|
$85,258,075,000 | 12.57% |
| Replimune Group Inc |
No change
4,866,449
|
$43,798,041,000 | 6.46% |
| Bicycle Therapeutics plc |
Opened
2,122,892
|
$42,967,334,000 | 6.34% |
| Achilles Therapeutics Plc |
No change
2,390,050
|
$1,947,891,000 | 0.29% |
| No transactions found | |||
| Showing first 500 out of 6 holdings | |||